Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Friday. The company reported $1.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.23, MarketWatch Earnings reports. The firm had revenue of $10.87 billion for the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. Merck & Co., Inc.’s revenue was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.30 EPS. Merck & Co., Inc. updated its FY 2020
Pre-Market guidance to 5.63-5.78 EPS and its FY20 guidance to $5.63-5.78 EPS.

MRK opened at $80.24 on Friday. Merck & Co., Inc. has a one year low of $65.25 and a one year high of $92.64. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market capitalization of $202.53 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 2.20 and a beta of 0.48. The business’s 50-day simple moving average is $77.65 and its 200-day simple moving average is $79.99.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.61 dividend. The ex-dividend date is Monday, September 14th. This represents a $2.44 annualized dividend and a yield of 3.04%. Merck & Co., Inc.’s dividend payout ratio is presently 47.01%.

In other Merck & Co., Inc. news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $76.02, for a total transaction of $380,100.00. Following the completion of the sale, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $387,702. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Julie L. Gerberding sold 36,285 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $80.00, for a total value of $2,902,800.00. Following the sale, the executive vice president now directly owns 62,862 shares of the company’s stock, valued at $5,028,960. The disclosure for this sale can be found here. 0.28% of the stock is owned by corporate insiders.

Several analysts have recently issued reports on MRK shares. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Monday, June 8th. UBS Group cut their target price on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Guggenheim decreased their price target on shares of Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. SVB Leerink cut their price objective on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 29th. Finally, Wolfe Research cut Merck & Co., Inc. from an “outperform” rating to a “peer perform” rating in a research note on Friday, June 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $94.15.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What is the Consumer Price Index (CPI)?

Earnings History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.